Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre‐Seasonal Short Courses of Allergen‐Specific Immunotherapy: A Long‐Term Open‐Label Extension Study
Clinical & Experimental Allergy · 2026-08 · 56 (8) · 893-903
DOI: 10.1111/cea.70323 ↗At a glance
Randomisierte kontrollierte Studie in Clinical & Experimental Allergy, published online on 2026-04-30. Written by Ralph Mösges and 15 co-authors. Institution: ClinCompetence Cologne GmbH, Cologne, Germany. Major MEDLINE topics: Rhinitis, Allergic, Seasonal, Desensitization, Immunologic, Betula, Pollen. Cited 1 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY 4.0). Funded by: Inmunotek S.L..
Abstract (original language)
Background
Mannan‐conjugated allergoids represent an effective option for treating allergic diseases. This study evaluated the clinical impact of the mannan‐conjugated, polymerised birch pollen allergoid EP‐088_T502 in patients with birch pollen‐induced allergic rhinoconjunctivitis over 3 years.
Methods
Following up to a double‐blind, placebo‐controlled dose‐finding study, in this open, long‐term extension study, 154 birch pollen‐allergic patients were enrolled in Germany. Patients were treated with a cumulative dose of 48,000 mTU EP‐088_T502 administered subcutaneously over five pre‐seasonal visits in each of the two treatment years (2021, 2022) with a subsequent follow‐up year in 2023. The primary efficacy endpoint was the combined symptom and medication score (CSMS) during the peak birch pollen season, which was compared with the CSMS of the placebo group during the peak pollen season of 2020. Safety, tolerability, and immunogenicity were also analysed.
Results
Compared to the placebo group of the preceding study, median CSMS during the peak birch pollen seasons showed reductions of 47.5% in 2021 ( p < 0.001), 51.8% in 2022 ( p < 0.001), and 36.5% in 2023 ( p < 0.001). Median daily symptom scores were reduced by 40.7% in 2021 ( p < 0.001), 40.7% in 2022 ( p < 0.001), and 25.6% in 2023 ( p < 0.010). Median daily medication scores reached 0.07 in 2021 and 0.04 in 2022 ( p < 0.001) and were reduced by 65.9% in 2023 ( p < 0.003). Immunological responses showed a 4.82‐fold increase in Bet v1 sIgG4 ( p = 0.001) and a marked decrease (−65.5%, p = 0.001) in the sIgE/sIgG4 ratio after the first treatment phase. EP‐088_T502 demonstrated good safety and tolerability, with only six mild to moderate systemic allergic reactions (Grade I/II). No epinephrine was used.
Conclusion
In this open‐label study, two consecutive years of pre‐seasonal short‐course allergen immunotherapy (AIT) with EP‐088_T502 markedly reduced symptoms and medication need in patients with birch pollen‐induced rhinoconjunctivitis. Persistent therapeutic effects observed during the follow‐up year, although limited by attrition of the study population, suggest sustained clinical improvement and indicate the potential disease‐modifying impact of this treatment regimen.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- ClinCompetence Cologne GmbH, Cologne, Germany.
- Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany.
- Center for Rhinology & Allergology, Wiesbaden, Germany.
- Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
- Inmunotek S.L., Madrid, Spain.
- Department of Otorhinolaryngology, Technische Universität Dresden, Dresden, Germany.
ORCID profiles: Ralph Mösges, Friederike Hüffmeier, Ludger Klimek, Oliver Pfaar, Christian Neuhof, Anna Rybachuk, Cengizhan Acikel, Hacer Sahin, Silke Allekotte, Sandra Del Pozo, José Luis Subiza, Miguel Casanovas, Mandy Cuevas, Laura Day, Lea Radtke, Esther Raskopf
Funding
- Inmunotek S.L.
Cite
APA
Mösges, R., Hüffmeier, F., Klimek, L., Pfaar, O., Neuhof, C., Rybachuk, A., Acikel, C., Sahin, H., Allekotte, S., Del Pozo, S., Subiza, J. L., Casanovas, M., Cuevas, M., Day, L., Radtke, L., & Raskopf, E. (2026). Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre‐Seasonal Short Courses of Allergen‐Specific Immunotherapy: A Long‐Term Open‐Label Extension Study. Clinical & Experimental Allergy, 56(8), 893-903. https://doi.org/10.1111/cea.70323
Vancouver
Mösges R, Hüffmeier F, Klimek L, Pfaar O, Neuhof C, Rybachuk A, et al. Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre‐Seasonal Short Courses of Allergen‐Specific Immunotherapy: A Long‐Term Open‐Label Extension Study. Clinical & Experimental Allergy. 2026;56(8):893-903. doi:10.1111/cea.70323
BibTeX
@article{Msges2026,
author = {Mösges, Ralph and Hüffmeier, Friederike and Klimek, Ludger and Pfaar, Oliver and Neuhof, Christian and Rybachuk, Anna and Acikel, Cengizhan and Sahin, Hacer and Allekotte, Silke and Del Pozo, Sandra and Subiza, José Luis and Casanovas, Miguel and Cuevas, Mandy and Day, Laura and Radtke, Lea and Raskopf, Esther},
title = {Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre‐Seasonal Short Courses of Allergen‐Specific Immunotherapy: A Long‐Term Open‐Label Extension Study},
journal = {Clinical & Experimental Allergy},
year = {2026},
volume = {56},
number = {8},
pages = {893--903},
doi = {10.1111/cea.70323}
}
EUVIMED